Global Newsroom

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

CSL continues to provide medicines to patients around the world.

CSL is pleased to confirm that the final stages of manufacturing of the AstraZeneca COVID-19 vaccine for Australia are planned to commence next week, with first doses on track for release towards the end of March, subject to approval by the Therapeutic Goods Administration (TGA).

24 healthy volunteers to be recruited for study of plasma-derived COVID-19 Immunoglobulin

CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne.

Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Financial Officer (CFO.) Ms Linton will be based at CSL’s Head Office in Melbourne and will join CSL’s Global Leadership Group.

Development of the University of Queensland’s vaccine candidate remains CSL’s priority.

The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect.

Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care.

Less than a third of surveyed healthcare professionals (HCPs) in Australia encounter a rare disease patient more than once every six months.

Across APAC, 94% of rare conditions have no approved medical treatment, highlighting need to shift towards the provision of non-medical services.

Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia